Blog

Low-Dose Naltrexone (LDN) in the Management of Chronic Pain and Inflammation of Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders Chronic inflammatory diseases are complex to treat and have an impact on a large number of patients. Since the 1990s, opioid prescriptions have been increasing in prevalence in chronic inflammatory and neuropathic conditions. However, most opioids are considered less effective or have unproven efficacy in chronic conditions such as multiple sclerosis, fibromyalgia, and Crohn's disease.  Due to the difficulty of treating these diseases and their great impact on quality of life, patients often seek complementary or functional medicine options to obtain relief from symptoms. Naltrexone is a mu-opioid receptor antagonist indicated [...]

How is it possible that one medication can impact such a wide range of disorders? The disorders listed below all share a particular feature: in all of them, the immune system plays a central role. Low blood levels of endorphins are generally present, contributing to the disease-associated immune deficiencies. download- click this link Proposed-uses-of-LowDoseNaltrexone Are there any side effects or cautionary warnings? LDN is typically well tolerated. Occasionally, during the first week's use of LDN, patients may complain of some difficulty sleeping. This rarely persists after the first week. So a typical dose started working with your provider and Good Life Pharmacy would be to titrate from 1.5mg at bedtime for 1 week, [...]

Low Dose Naltrexone (LDN) Naltrexone is a long-acting oral opiate antagonist which is approved for the treatment of alcohol addiction (50mg tablet taken daily). The mechanism of action is complete opiate blockade, which removes the pleasure sensation derived from drinking alcohol (created by endorphins). Low Dose Naltrexone (LDN) in the range of 3-4.5 mg per day has been shown to have the opposite effect - brief opiate receptor blockade with resulting upregulation of endogenous opiate production. Through the work of Bihari and Zagon, it has been determined that the level of the endogenous opiate met-enkephalin is increased by LDN. Met-enkephalin is involved in regulating cell proliferation and can inhibit cancer cell growth in [...]